Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Andrew W. Roberts(The Royal Melbourne Hospital), John F. Seymour(The Royal Melbourne Hospital), Steven Coutré(Georgetown University), Stephan Stilgenbauer(Universität Ulm), Jacqueline Nielsen(AbbVie (United States)), Thomas J. Kipps(University of California San Diego), Matthew S. Davids(Dana-Farber Cancer Institute), Brenda Chyla(AbbVie (United States)), Michael Hallek(Integrated Oncology (United States)), Shuo Ma(Nantong University), Barbara Eichhorst(University of Cologne), William G. Wierda(University of Maryland, Baltimore), Jalaja Potluri(AbbVie (United States)), Su Young Kim(Yonsei University), Kathryn Humphrey(Roche (United Kingdom)), John C. Byrd(University of Cincinnati), Maria Verdugo(AbbVie (United States)), Lang Zhou(Qingdao University)
Blood
April 25, 2019
10.1182/blood.2018882555
Cited by 175

Related Papers

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k